The strong clinical data could lead to accelerated regulatory approval and commercialization. Traders should monitor for potential partnership announcements or licensing deals with larger pharmaceutical companies.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 15 $1.36entry
- T+1 · 7mo ago −5.88%α −6.14% · $1.28
- T+5 · 7mo ago −5.15%α −6.79% · $1.29
- T+20 · 6mo ago −19.12%α −25.16% · $1.10
- T+60 · 4mo ago −43.10%α −51.23% · $0.7739
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology announced positive interim Phase 2 clinical trial data for its drug PDS01ADC in treating metastatic colorectal cancer, showing a 78% objective response rate and 85% 2-year survival rate compared to 35% in a parallel trial.
Key Facts
- PDS01ADC showed 77.8% objective response rate (ORR) at 6 months vs 35% in parallel trial
- 24-month survival rate was approximately 85% vs 40% in parallel trial
- Data published in Journal of Clinical Oncology (JCO) Oncology Advances
- Trial conducted in unresectable microsatellite stable (MSS) or mismatch repair-proficient p(MMR) colorectal liver metastases
- PDS01ADC is a tumor-targeted immunocytokine designed to deliver Interleukin-12 (IL-12) directly to tumors
Financial Impact
Significant improvement in clinical outcomes with 77.8% ORR vs 35% in control group and 85% 2-year survival vs 40% in control group
Risk Factors
- Phase 2 data is still preliminary and may not translate to Phase 3 success
- Competitors in the colorectal cancer space could impact market potential
- The company's small market cap ($59M) makes it vulnerable to volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-014693 |
| Document: ef20070560_ex99-1.htm | 0001140361-26-014693 |
| Document: 0001140361-26-014693-index-headers.html | 0001140361-26-014693 |
| Document: 0001140361-26-014693-index.html | 0001140361-26-014693 |
| Document: 0001140361-26-014693.txt | 0001140361-26-014693 |
Track record
28 reports on PDSB
7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers